Let's see what happens if/when Blarcamesine is approved for Rett. I'll guess it's a back of the paper blurb in the newspapers you cited. If there's approval for Alzheimer's or Parkinson's, my guess is we'll see the front page or two.
Right now to the NYT or WSJ, Anavex is one of about a dozen promising companies working on neurological disorders. When there's legitimate news to report that the masses will understand simply by reading the headline, it will be reported. And if it isn't, so what?
The only report I am interested in reading will be from Stat News, written by Adam Feuerstein, either acknowledging he was wrong or publicly denouncing the FDA. But we all know that we'll see neither, as he and others (including many posters here) will slip silently into the night and will re-emerge with another early stage biotech to short.
If the 1.87 number being thrown around is a significant effect size for the ideal patient, and this data has been peer-reviewed, I would dare to say that's the nail in the coffin for shorts regarding the Rett story. And worst case even if Anavex were simply a Rett drug manufacturer, the profits would still be sufficient.
News 
Market Data 
Discover 
AI
